Patents Examined by Kortney L Klinkel
  • Patent number: 10233170
    Abstract: The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-? superfamily such as Nodal or Activin.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: March 19, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Donald Payan, Marina Gelman, Todd Kinsella
  • Patent number: 10227357
    Abstract: Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: March 12, 2019
    Assignee: Plexxikon Inc.
    Inventors: Jack Lin, John Buell, Katrina Chan, Todd Ewing, Prabha Ibrahim, Marika Nespi, Phuongly Pham, Songyuan Shi, Wayne Spevak, Guoxian Wu, Jiazhong Zhang, Ying Zhang
  • Patent number: 10227330
    Abstract: The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 12, 2019
    Assignee: YUHAN CORPORATION
    Inventors: Hyun-Joo Lee, Dong-Hoon Kim, Tae-Kyun Kim, Young-Ae Yoon, Jae-Young Sim, Myung-Hun Cha, Eun-Jung Jung, Kyoung-Kyu Ahn, Tai-Au Lee
  • Patent number: 10220048
    Abstract: Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: March 5, 2019
    Assignee: AERPIO THERAPEUTICS, INC.
    Inventors: Kevin Peters, Robert Shalwitz
  • Patent number: 10220049
    Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: March 5, 2019
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Yunik Chang, Gordon J. Dow
  • Patent number: 10220039
    Abstract: A method of treating polycystic kidney disease in a subject comprises administering to the subject an effective amount of a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: March 5, 2019
    Assignee: Genzyme Corporation
    Inventors: Thomas A. Natoli, Oxana Ibraghimov-Beskrovnaya, John P. Leonard, Nelson S. Yew, Seng H. Cheng
  • Patent number: 10220008
    Abstract: Using high-throughput screening, in an oxygen-glucose deprivation (OGD) model, isoxsuprine hydrochloride was identified as a potent neuroprotective compound. In an animal middle artery occlusion (MCAO) model of transient focal ischemia, isoxsuprine significantly reduced infarct volume compared to vehicle. The invention, therefore, provides methods of treatment and pharmaceutical compositions that are useful in the treatment and prevention of a wide-variety of ischemia-related injuries, including stroke.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: March 5, 2019
    Assignee: STC.UNM
    Inventor: Jeff Wade Hill
  • Patent number: 10213424
    Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: February 26, 2019
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Alain Cuine, Didier Hoarau, Pauline Romain
  • Patent number: 10213474
    Abstract: The present invention relates to a composition comprising a hydrophilic drug and an amphiphilic carbohydrate compound for use in therapy wherein the composition is intranasally administered to the human or animal body. The composition can be used to treat a variety of disorders, including schizophrenia, obesity, pain and sleep disorders, psychiatric diseases, neurodegenerative conditions, brain cancers and infective diseases.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: February 26, 2019
    Assignee: Nanomerics LTD
    Inventors: Ijeoma Uchegbu, Andreas Schatzlein, Lisa Godfrey, Katerina Lalatsa, Antonio Iannitelli
  • Patent number: 10207020
    Abstract: An identification device that combines an antimicrobial coating with a printable substrate. For example, the invention includes a wristband with a face stock supporting indicia which are applied on (such as through thermal transfer printing) or through (such as through direct thermal printing) an antimicrobial layer. The antimicrobial layer is preferably a coating or varnish that is applied as the outermost layer and can bind with thermal transfer printing ink or supports pass through of direct thermal printing on a chemically receptive sublayer. The antimicrobial varnish includes varnish compounds and antimicrobial compounds such as a silver zeolite ion that is configured to react to moisture with a controlled release of microbial disinfectant. Preferably, the wristband is a hospital wristband bearing on-site printed identification indicia for a patient.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: February 19, 2019
    Assignee: Zebra Technologies Corporation
    Inventors: Gene Allen Hofer, David Macedon
  • Patent number: 10206919
    Abstract: The embodiments described herein include methods and formulations for treating vasculitis. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: February 19, 2019
    Assignee: IRR, Inc.
    Inventor: Bruce Chandler May
  • Patent number: 10202370
    Abstract: Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof: Wherein n, R1, R2, R3, R4, R5, A, Q and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: February 12, 2019
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Abdellah Benjahad, Claire Schalon, Didier Pez, Emmanuel Chevenier, Franck Sandrinelli, Jason Martin, Willy Picoul
  • Patent number: 10201537
    Abstract: The embodiments described herein include methods and formulations for treating autoimmune disorders. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: February 12, 2019
    Assignee: IRR, Inc.
    Inventor: Bruce Chandler May
  • Patent number: 10195142
    Abstract: A method of making an oral soluble film, containing at least one active agent, includes providing a well of a predetermined size; depositing a film forming composition in the well; depositing an active agent composition in the well, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming an admixture in the well; and drying the admixture in the well. Alternatively, the method includes providing a well of a predetermined size; depositing a film forming composition including at least one active agent in the well, the film forming composition having a viscosity below 2000 centipoise; and drying the film forming composition in the well.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: February 5, 2019
    Inventors: Richard C. Fuisz, Joseph M. Fuisz
  • Patent number: 10188377
    Abstract: The present invention contemplates a hand-held and hand-operable stitching device capable of securely placing a single interrupted suture through a wound using sterile suturing material with a single squeeze of the device's arms. Operating substantially faster than a surgeon, the compact and lightweight device employs an intuitive stapler-like structure and a center assembly capable of closing a wound with traditional suturing material secured by anchors that remain on either side of the wound. The apparatus employs needle-suture units stored in a center assembly and deployed individually when the device is actuated. When actuated, an epicyclic gear train within a center assembly causes a needle-suture unit to rotate through a circular path through the tissue, bringing the edges of separated tissue together. The suture thread is then secured in its position with anchors and the needle is then disjointed from the suture thread with a blade.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: January 29, 2019
    Inventors: Ruchi Patel, Giovanni Sanchez
  • Patent number: 10188106
    Abstract: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against fungal diseases or insect damages, and the corresponding methods of protection by application of the said composition. More precisely, the subject of the present invention is a pesticide composition based on a tetrazolyloxime derivative and a fungicide or an insecticide active substance or compound.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: January 29, 2019
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Pierre-Yves Coqueron, Marie-Claire Grosjean-Cournoyer, Pierre Hutin, Gilbert Spica, Arnd Voerste, Ulrike Wachendorff-Neumann
  • Patent number: 10172772
    Abstract: Compositions and methods for lightening skin are provided. A method for lightening skin may include the step of identifying skin where lightening or whitening is desired and topically applying to the skin a composition including (a) a skin lightening agent comprising a canola extract and (b) a cosmetically acceptable carrier. A method for treating hyperpigmentation may include the step of identifying skin containing areas of hyperpigmentation and topically applying to the skin a composition including (a) a canola extract and (b) a cosmetically acceptable carrier.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: January 8, 2019
    Assignee: KGK Science, Inc.
    Inventors: Najla Guthrie, Robert Allen Guthrie
  • Patent number: 10174279
    Abstract: An embodiment of the present invention provides an apparatus and method for expanding skin capable of expanding autologous skin to the maximum extent and performing a tissue culture of skin at the outside of the body. While an apparatus for expanding autologous skin of body's outside in general takes a form of expanding skin by applying a certain amount of constant force for a period of time regardless of the skin properties, the apparatus and method for expanding skin according to the embodiment of the present invention expands the skin to the maximum extent without rupturing the skin based on measurements of elasticity of the skin to find the maximum expanded area reachable just before rupturing of the skin.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: January 8, 2019
    Assignee: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventors: Yun Jeong Song, Hwi Gang Kim, Jung Wook Suh, Eun Chang Choi, Chang Hyuk Hong, Dae Sik Kim, Hyung Soo Lee
  • Patent number: 10159651
    Abstract: A method for manufacturing a therapeutic agent delivery system includes forming a first mixture with a plurality of microparticles, the microparticles containing a therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan. The method also includes forming a second mixture from ingredients including the first mixture, chitosan, a hydration promoter, a microparticle adhesion inhibitor, and a microparticle aggregation inhibitor, freezing the second mixture in a bath containing an aqueous alcoholic solution at a temperature above the freezing temperature of the aqueous alcoholic solution and at most ?40° C., to form a frozen layer precursor, and drying the frozen layer precursor to form a porous polymeric matrix with microparticles embedded within the matrix.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: December 25, 2018
    Assignee: Privo Technologies, Inc.
    Inventors: Manijeh Nazari Goldberg, Aaron Manzi, Brandon LaPorte, Amritpreet Birdi
  • Patent number: 10159724
    Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: December 25, 2018
    Assignees: Icahn School of Medicine at Mount Sinai, Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science
    Inventors: Edward H. Schuchman, Erich Gulbins, Anthony Futerman, Yael Pewzner-Jung